Joseph Catanzaro analyst PIPER SANDLER

Currently, out of the existing stock ratings of Joseph Catanzaro - 199 which are a Buy (76.83%), 60 which are a Hold (23.17%)

Joseph Catanzaro

Work Performance Price Targets & Ratings Chart

Analyst Joseph Catanzaro works at PIPER SANDLER and is covering Healthcare, Consumer Cyclical sectors with 482 price targets and ratings displayed on 34 stocks.

Joseph Catanzaro's average stock forecast success ratio is 41.32% with an average time for price targets to be met of 115.21 days.

Most recent stock forecast was given on BMEA, at 26-Jun-2023.

Wall Street Analyst Joseph Catanzaro

Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for CPRX (CATALYST PHARMACEUTICALS) at 11/10/2021. The price target of $7 was fulfilled within 1 day with a profit of $0.55 (8.53%) receiving and performance score of 85.27.

Average potential price target upside

AADI AERI Aerie Pharmaceuticals CLVS Clovis Oncology CPRX Catalyst Pharmaceuticals CRDF FIGS Figs GBT Global Blood Therapeutics HALO Halozyme Therapeutics IMGN ImmunoGen IMMU IOVA Iovance Biotherapeutics LPTX NCNA NuCana plc NLTX OCUL Ocular Therapeutix RAIN SGEN Seattle Genetics CTMX CytomX Therapeutics EPIX ESSA Pharma HARP Harpoon Therapeutics IMAB IMAB Sponsored ADR MRKR Marker Therapeutics RPTX Repare Therapeutics BMEA CNTB DAWN GRCL IBRX SNSE KROS Keros Therapeutics NRIX Nurix Therapeutics OYST STML ACHL

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

45

$40.16 (829.75%)

45

1 months 23 days ago

0/6 (0%)

$33.39 (349.37%)

Buy

45

6 months 4 days ago

0/1 (0%)

$20.97 (87.27%)

Buy

50

$45.7 (1062.79%)

45

1 years 10 months 10 days ago

0/2 (0%)

$24.5 (106.54%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Joseph Catanzaro is most bullish on?

Potential upside of $79.18 has been obtained for KROS (KEROS THERAPEUTICS)

Which stock is Joseph Catanzaro is most reserved on?

Potential downside of $2.47 has been obtained for IBRX

What Year was the first public recommendation made by Joseph Catanzaro?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart